Loading the session
Loading the session
Loading instrument
$31.20
−4.59%DelayedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:18 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: −8.2% (SPY −1.6%, XLV +13.5%). 3 months: −26.3% (SPY −0.4%, XLV +15.5%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: DFTX, SPY and XLV · as of 4 Nov 2026
The 4 Nov 2026 close of $32.70 was 11.8% below its 50-day average ($37.08) and 9.5% above its 200-day average ($29.86).
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
10.0M shares were sold short at the 15 Oct 2026 settlement, 7.5% of the 134.4M shares outstanding; covering them would take 4.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
June 24, 2026
+16.45%June 22, 2026
+49.80%January 20, 2026
+11.50%